尖峰集团 (600668.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

5.6x

Market Cap

CNY 2.99B

MomentumView details →

1D Return

−1.23%

YTD Return

−33.81%

RSI (14)

50.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

5.6x

Market Cap

CNY 2.99B

RSI (14)

50.6

MomentumView details →

1D Return

−1.23%

YTD Return

−33.81%

ProfitabilityView details →

Gross Margin

20.42%

Net Margin

−7.49%

EBITDA Margin

28.76%

ROE (TTM)

−3.44%

ROA (TTM)

−2.40%

Asset Turnover

0.32x

GrowthView details →

Revenue YoY

−11.84%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−10.32%

EPS CAGR 3Y

+5.98%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.15x

Current Ratio

0.81x

Quick Ratio

0.59x

Div Yield

1.34%

Div Rate

CNY 0.10

Div Growth 1Y

+0.00%

Financials snapshotView financials →

Revenue (TTM)

2.52B

Net Income (TTM)

−188.70M

Op. CF (TTM)

247.88M

Latest newsMore news →

Jianfeng Group's subsidiary Anhui Jianfeng Beika Pharmaceutical received approval from China's National Medical Products Administration to market the active pharmaceutical ingredient methyldopa in China.3d ago

Jianfeng Group announced its first-half 2026 results: main business revenue of 1.115 billion yuan, down 10.26% year-on-year; main business cost of 941 million yuan, down 1.60%; gross margin of 15.64%, down 7.43 percentage points.5d ago

Similar companies

Titan America S.A.TTAM Boise Cascade CompanyBCC 三峡新材600293.SH United States Lime & Minerals, Inc.USLM 狮头股份600539.SH Asia Cement (China) Holdings Corporation00743.HK Find similar companies →

Latest newsMore news →

Jianfeng Group's subsidiary Anhui Jianfeng Beika Pharmaceutical received approval from China's National Medical Products Administration to market the active pharmaceutical ingredient methyldopa in China.3d ago Jianfeng Group announced its first-half 2026 results: main business revenue of 1.115 billion yuan, down 10.26% year-on-year; main business cost of 941 million yuan, down 1.60%; gross margin of 15.64%, down 7.43 percentage points.5d ago Jianfeng Group's subsidiary Jianfeng Pharmaceutical received a Drug Registration Certificate for Tedizolid Phosphate for Injection from the National Medical Products Administration.42d ago